Comparing AngioSoma (OTCMKTS:SOAN) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Profitability

This table compares Calliditas Therapeutics AB (publ) and AngioSoma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
AngioSoma	N/A	N/A	-1,245.34%

Risk & Volatility

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500.

Insider and Institutional Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 0.0% of AngioSoma shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Calliditas Therapeutics AB (publ) and AngioSoma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A

AngioSoma has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

Summary

Calliditas Therapeutics AB (publ) beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.